MilliporeSigma conducted a global market survey on fully closed processing for biopharmaceutical manufacturing and gathered industry viewpoints on the topic. This paper provides key findings from the research, as well as insights and perspectives from industry experts on the shift towards closed processing and its effects on the facility of the future.
The future of bioprocessing lies not in isolated, traditional systems but in closed, connected, and continuously enabled processes. This new approach to manufacturing is being leveraged by the industry to manage increasingly complex product pipelines and gain production efficiencies to reduce contamination risks, increase flexibility, and decrease costs.
Survey participants defined drivers and challenges associated with the adoption and implementation of fully closed processing. The main driver was defined as reduced risk of contamination, and greatest challenge was said to be product and technology gaps.
When asked how many new or renovated fully closed processing facilities their organizations plan to implement in the coming years, respondents indicated that there should be a noticeable increase in both new and renovated facilities in the coming five to ten years.
The adoption of fully closed processing will be an evolution. Closed processing will continue to advance as the biopharmaceutical industry creates the blueprint for the facility of the future. The advantages of closed systems are numerous, with benefits extending beyond immediate financial gains and time efficiencies, and contributing substantially to overarching industry goals.
For a more detailed review of the survey results, please download our whitepaper.